Sanofi (EURONEXT: SAN and NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass.

Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Japan Inc. ("Pfizer") announced that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products

Over 20,000 employees of Roche from 113 Roche sites marked the International Day of the African Child by walking and collecting donations for children in need as part of the 9th Roche Children's Walk.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved PerjetaTM (pertuzumab). Perjeta is approved in combination with Herceptin® (trastuzumab) and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease.

In support of its commitment to maximize growth opportunities in China, Eli Lilly and Company (NYSE: LLY) announced an increase of its network of manufacturing capabilities in this key emerging market country through an expanded collaboration with Novast Laboratories, LTD.

New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment[1].